{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T22:30:06Z","timestamp":1788820206842,"version":"build-2803163510"},"reference-count":89,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,23]],"date-time":"2022-11-23T00:00:00Z","timestamp":1669161600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,23]],"date-time":"2022-11-23T00:00:00Z","timestamp":1669161600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100015736","name":"Folkh\u00e4lsan Research Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100015736","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Helsinki University Central Hospital Research Funds","award":["TYH2018207"],"award-info":[{"award-number":["TYH2018207"]}]},{"DOI":"10.13039\/100010113","name":"Wilhelm och Else Stockmanns Stiftelse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010113","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010116","name":"Medicinska Underst\u00f6dsf\u00f6reningen Liv och H\u00e4lsa","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010116","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Fonden","doi-asserted-by":"publisher","award":["NNF OC0013659"],"award-info":[{"award-number":["NNF OC0013659"]}],"id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006306","name":"Sigrid Jus\u00e9liuksen S\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006306","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002341","name":"Academy of Finland","doi-asserted-by":"crossref","award":["299200"],"award-info":[{"award-number":["299200"]}],"id":[{"id":"10.13039\/501100002341","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100002341","name":"Academy of Finland","doi-asserted-by":"crossref","award":["316664"],"award-info":[{"award-number":["316664"]}],"id":[{"id":"10.13039\/501100002341","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001648","name":"European Foundation for the Study of Diabetes","doi-asserted-by":"publisher","award":["Young Investigator Research Award funds"],"award-info":[{"award-number":["Young Investigator Research Award funds"]}],"id":[{"id":"10.13039\/501100001648","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001648","name":"European Foundation for the Study of Diabetes","doi-asserted-by":"publisher","award":["EFSD award supported by EFSD\/Sanofi European Diabetes Research Programme in Macrovascular Complications"],"award-info":[{"award-number":["EFSD award supported by EFSD\/Sanofi European Diabetes Research Programme in Macrovascular Complications"]}],"id":[{"id":"10.13039\/501100001648","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Genome Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Dyslipidemia is a major risk factor for cardiovascular disease, and diabetes impacts the lipid metabolism through multiple pathways. In addition to the standard lipid measurements, apolipoprotein concentrations provide added awareness of the burden of circulating lipoproteins. While common genetic variants modestly affect the serum lipid concentrations, rare genetic mutations can cause monogenic forms of hypercholesterolemia and other genetic disorders of lipid metabolism. We aimed to identify low-frequency protein-altering variants (PAVs) affecting lipoprotein and lipid traits.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We analyzed whole-exome (WES) and whole-genome sequencing (WGS) data of 481 and 474 individuals with type 1 diabetes, respectively. The phenotypic data consisted of 79 serum lipid and apolipoprotein phenotypes obtained with clinical laboratory measurements and nuclear magnetic resonance spectroscopy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The single-variant analysis identified an association between the\n                      <jats:italic>LIPC<\/jats:italic>\n                      p.Thr405Met (rs113298164) and serum apolipoprotein A1 concentrations (\n                      <jats:italic>p<\/jats:italic>\n                      =7.8\u00d710\n                      <jats:sup>\u22128<\/jats:sup>\n                      ). The burden of PAVs was significantly associated with lipid phenotypes in\n                      <jats:italic>LIPC<\/jats:italic>\n                      ,\n                      <jats:italic>RBM47<\/jats:italic>\n                      ,\n                      <jats:italic>TRMT5<\/jats:italic>\n                      ,\n                      <jats:italic>GTF3C5<\/jats:italic>\n                      ,\n                      <jats:italic>MARCHF10<\/jats:italic>\n                      , and\n                      <jats:italic>RYR3<\/jats:italic>\n                      (\n                      <jats:italic>p<\/jats:italic>\n                      &lt;2.9\u00d710\n                      <jats:sup>\u22126<\/jats:sup>\n                      ). The\n                      <jats:italic>RBM47<\/jats:italic>\n                      gene is required for apolipoprotein B post-translational modifications, and in our data, the association between\n                      <jats:italic>RBM47<\/jats:italic>\n                      and apolipoprotein C-III concentrations was due to a rare 21 base pair p.Ala496-Ala502 deletion; in replication, the burden of rare deleterious variants in\n                      <jats:italic>RBM47<\/jats:italic>\n                      was associated with lower triglyceride concentrations in WES of &gt;170,000 individuals from multiple ancestries (\n                      <jats:italic>p<\/jats:italic>\n                      =0.0013). Two PAVs in\n                      <jats:italic>GTF3C5<\/jats:italic>\n                      were highly enriched in the Finnish population and associated with cardiovascular phenotypes in the general population. In the previously known\n                      <jats:italic>APOB<\/jats:italic>\n                      gene, we identified novel associations at two protein-truncating variants resulting in lower serum non-HDL cholesterol (\n                      <jats:italic>p<\/jats:italic>\n                      =4.8\u00d710\n                      <jats:sup>\u22124<\/jats:sup>\n                      ), apolipoprotein B (\n                      <jats:italic>p<\/jats:italic>\n                      =5.6\u00d710\n                      <jats:sup>\u22124<\/jats:sup>\n                      ), and LDL cholesterol (\n                      <jats:italic>p<\/jats:italic>\n                      =9.5\u00d710\n                      <jats:sup>\u22124<\/jats:sup>\n                      ) concentrations.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      We identified lipid and apolipoprotein-associated variants in the previously known\n                      <jats:italic>LIPC<\/jats:italic>\n                      and\n                      <jats:italic>APOB<\/jats:italic>\n                      genes, as well as PAVs in\n                      <jats:italic>GTF3C5<\/jats:italic>\n                      associated with LDLC, and in\n                      <jats:italic>RBM47<\/jats:italic>\n                      associated with apolipoprotein C-III concentrations, implicated as an independent CVD risk factor. Identification of rare loss-of-function variants has previously revealed genes that can be targeted to prevent CVD, such as the LDL cholesterol-lowering loss-of-function variants in the\n                      <jats:italic>PCSK9<\/jats:italic>\n                      gene. Thus, this study suggests novel putative therapeutic targets for the prevention of CVD.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13073-022-01135-6","type":"journal-article","created":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T12:15:22Z","timestamp":1669292122000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Whole-exome sequencing identifies novel protein-altering variants associated with serum apolipoprotein and lipid concentrations"],"prefix":"10.1186","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4322-6942","authenticated-orcid":false,"given":"Niina","family":"Sandholm","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronja","family":"Hotakainen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jani K.","family":"Haukka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanny","family":"Jansson Sigfrids","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma H.","family":"Dahlstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anni A.","family":"Antikainen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erkka","family":"Valo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Syreeni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elina","family":"Kilpel\u00e4inen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasia","family":"Kyt\u00f6l\u00e4","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aarno","family":"Palotie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valma","family":"Harjutsalo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Forsblom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4055-6954","authenticated-orcid":false,"given":"Per-Henrik","family":"Groop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the FinnDiane Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,23]]},"reference":[{"key":"1135_CR1","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1016\/S0140-6736(17)32152-9","volume":"390","author":"M Naghavi","year":"2017","unstructured":"Naghavi M, Abajobir AA, Abbafati C, Abbas KM, Abd-Allah F, Abera SF, et al. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390:1151\u2013210.","journal-title":"Lancet."},{"key":"1135_CR2","doi-asserted-by":"publisher","first-page":"2759","DOI":"10.1111\/dom.13456","volume":"20","author":"V Harjutsalo","year":"2018","unstructured":"Harjutsalo V, Thomas MC, Forsblom C, Groop P-H, FinnDiane Study Group. Risk of coronary artery disease and stroke according to sex and presence of diabetic nephropathy in type 1 diabetes. Diabetes Obes Metab. 2018;20:2759\u201367.","journal-title":"Diabetes Obes Metab"},{"key":"1135_CR3","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1016\/j.metabol.2014.08.010","volume":"63","author":"L Wu","year":"2014","unstructured":"Wu L, Parhofer KG. Diabetic dyslipidemia. Metabolism. 2014;63:1469\u201379.","journal-title":"Metabolism."},{"key":"1135_CR4","doi-asserted-by":"publisher","first-page":"2374","DOI":"10.2337\/dc13-2873","volume":"37","author":"N Tolonen","year":"2014","unstructured":"Tolonen N, Forsblom C, M\u00e4kinen V-P, Harjutsalo V, Gordin D, Feodoroff M, et al. Different lipid variables predict incident coronary artery disease in patients with type 1 diabetes with or without diabetic nephropathy: the FinnDiane study. Diabetes Care. 2014;37:2374\u201382.","journal-title":"Diabetes Care"},{"key":"1135_CR5","doi-asserted-by":"publisher","first-page":"4329","DOI":"10.1038\/s41467-019-11954-8","volume":"10","author":"R Tabassum","year":"2019","unstructured":"Tabassum R, R\u00e4m\u00f6 JT, Ripatti P, Koskela JT, Kurki M, Karjalainen J, et al. Genetic architecture of human plasma lipidome and its link to cardiovascular disease. Nat Commun. 2019;10:4329.","journal-title":"Nat Commun"},{"key":"1135_CR6","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1038\/s41588-018-0222-9","volume":"50","author":"D Klarin","year":"2018","unstructured":"Klarin D, Damrauer SM, Cho K, Sun YV, Teslovich TM, Honerlaw J, et al. Genetics of blood lipids among 300,000 multi-ethnic participants of the Million Veteran Program. Nat Genet. 2018;50:1514\u201323.","journal-title":"Nat Genet"},{"key":"1135_CR7","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/ng.3300","volume":"47","author":"I Surakka","year":"2015","unstructured":"Surakka I, Horikoshi M, M\u00e4gi R, Sarin A-P, Mahajan A, Lagou V, et al. The impact of low-frequency and rare variants on lipid levels. Nat Genet. 2015;47:589\u201397.","journal-title":"Nat Genet"},{"key":"1135_CR8","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.1038\/ng.3977","volume":"49","author":"DJ Liu","year":"2017","unstructured":"Liu DJ, Peloso GM, Yu H, Butterworth AS, Wang X, Mahajan A, et al. Exome-wide association study of plasma lipids in >300,000 individuals. Nat Genet. 2017;49:1758\u201366.","journal-title":"Nat Genet"},{"key":"1135_CR9","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1038\/s41586-021-04103-z","volume":"599","author":"JD Backman","year":"2021","unstructured":"Backman JD, Li AH, Marcketta A, Sun D, Mbatchou J, Kessler MD, et al. Exome sequencing and analysis of 454,787 UK Biobank participants. Nature. 2021;599:628\u201334.","journal-title":"Nature."},{"key":"1135_CR10","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1126\/science.1222794","volume":"337","author":"MT Maurano","year":"2012","unstructured":"Maurano MT, Humbert R, Rynes E, Thurman RE, Haugen E, Wang H, et al. Systematic localization of common disease-associated variation in regulatory DNA. Science. 2012;337:1190\u20135.","journal-title":"Science."},{"key":"1135_CR11","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1681\/ASN.2016020231","volume":"28","author":"N Sandholm","year":"2017","unstructured":"Sandholm N, Van Zuydam N, Ahlqvist E, Juliusdottir T, Deshmukh HA, Rayner NW, et al. The genetic landscape of renal complications in type 1 diabetes. J Am Soc Nephrol. 2017;28:557\u201374.","journal-title":"J Am Soc Nephrol"},{"key":"1135_CR12","doi-asserted-by":"publisher","first-page":"12408","DOI":"10.1038\/s41598-018-29211-1","volume":"8","author":"N Sandholm","year":"2018","unstructured":"Sandholm N, Haukka JK, Toppila I, Valo E, Harjutsalo V, Forsblom C, et al. Confirmation of GLRA3 as a susceptibility locus for albuminuria in Finnish patients with type 1 diabetes. Sci Rep. 2018;8:12408.","journal-title":"Sci Rep"},{"key":"1135_CR13","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.ajhg.2021.11.021","volume":"109","author":"G Hindy","year":"2022","unstructured":"Hindy G, Dornbos P, Chaffin MD, Liu DJ, Wang M, Selvaraj MS, et al. Rare coding variants in 35 genes associate with circulating lipid levels-a multi-ancestry analysis of 170,000 exomes. Am J Hum Genet. 2022;109:81\u201396.","journal-title":"Am J Hum Genet"},{"key":"1135_CR14","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1056\/NEJMoa054013","volume":"354","author":"JC Cohen","year":"2006","unstructured":"Cohen JC, Boerwinkle E, Mosley TH, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med. 2006;354:1264\u201372.","journal-title":"N Engl J Med"},{"key":"1135_CR15","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1161\/CIRCGENETICS.114.000776","volume":"8","author":"NO Stitziel","year":"2015","unstructured":"Stitziel NO, Peloso GM, Abifadel M, Cefalu AB, Fouchier S, Motazacker MM, et al. Exome sequencing in suspected monogenic dyslipidemias. Circ Cardiovasc Genet. 2015;8:343\u201350.","journal-title":"Circ Cardiovasc Genet"},{"key":"1135_CR16","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.ajhg.2014.01.010","volume":"94","author":"LA Lange","year":"2014","unstructured":"Lange LA, Hu Y, Zhang H, Xue C, Schmidt EM, Tang Z-Z, et al. Whole-exome sequencing identifies rare and low-frequency coding variants associated with LDL cholesterol. Am J Hum Genet. 2014;94:233\u201345.","journal-title":"Am J Hum Genet"},{"key":"1135_CR17","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.1007\/s00018-020-03715-4","volume":"78","author":"R Tabassum","year":"2021","unstructured":"Tabassum R, Ripatti S. Integrating lipidomics and genomics: emerging tools to understand cardiovascular diseases. Cell Mol Life Sci. 2021;78:2565\u201384.","journal-title":"Cell Mol Life Sci"},{"key":"1135_CR18","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1001\/jamacardio.2019.3780","volume":"4","author":"AD Sniderman","year":"2019","unstructured":"Sniderman AD, Thanassoulis G, Glavinovic T, Navar AM, Pencina M, Catapano A, et al. Apolipoprotein B particles and cardiovascular disease: a narrative review. JAMA Cardiol. 2019;4:1287\u201395.","journal-title":"JAMA Cardiol"},{"key":"1135_CR19","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.atherosclerosis.2019.12.009","volume":"294","author":"P Ohukainen","year":"2020","unstructured":"Ohukainen P, Kuusisto S, Kettunen J, Perola M, J\u00e4rvelin M-R, M\u00e4kinen V-P, et al. Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease. Atherosclerosis. 2020;294:10\u20135.","journal-title":"Atherosclerosis."},{"key":"1135_CR20","doi-asserted-by":"publisher","first-page":"4165","DOI":"10.1172\/JCI127308","volume":"129","author":"JE Kanter","year":"2019","unstructured":"Kanter JE, Shao B, Kramer F, Barnhart S, Shimizu-Albergine M, Vaisar T, et al. Increased apolipoprotein C3 drives cardiovascular risk in type 1 diabetes. J Clin Invest. 2019;129:4165\u201379.","journal-title":"J Clin Invest"},{"key":"1135_CR21","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s11883-019-0791-9","volume":"21","author":"M-R Taskinen","year":"2019","unstructured":"Taskinen M-R, Packard CJ, Bor\u00e9n J. Emerging evidence that ApoC-III inhibitors provide novel options to reduce the residual CVD. Curr Atheroscler Rep. 2019;21:27.","journal-title":"Curr Atheroscler Rep"},{"key":"1135_CR22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003062","volume":"17","author":"TG Richardson","year":"2020","unstructured":"Richardson TG, Sanderson E, Palmer TM, Ala-Korpela M, Ference BA, Davey Smith G, et al. Evaluating the relationship between circulating lipoprotein lipids and apolipoproteins with risk of coronary heart disease: a multivariable Mendelian randomisation analysis. PLoS Med. 2020;17:e1003062.","journal-title":"PLoS Med"},{"key":"1135_CR23","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1056\/NEJMoa1308027","volume":"371","author":"AB J\u00f8rgensen","year":"2014","unstructured":"J\u00f8rgensen AB, Frikke-Schmidt R, Nordestgaard BG, Tybj\u00e6rg-Hansen A. Loss-of-function mutations in APOC3 and risk of ischemic vascular disease. N Engl J Med. 2014;371:32\u201341.","journal-title":"N Engl J Med"},{"key":"1135_CR24","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1016\/S0022-2275(20)39938-7","volume":"35","author":"M Chen","year":"1994","unstructured":"Chen M, Breslow JL, Li W, Leff T. Transcriptional regulation of the apoC-III gene by insulin in diabetic mice: correlation with changes in plasma triglyceride levels. J Lipid Res. 1994;35:1918\u201324.","journal-title":"J Lipid Res"},{"key":"1135_CR25","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1161\/ATVBAHA.110.220723","volume":"31","author":"S Caron","year":"2011","unstructured":"Caron S, Verrijken A, Mertens I, Samanez CH, Mautino G, Haas JT, et al. Transcriptional activation of apolipoprotein CIII expression by glucose may contribute to diabetic dyslipidemia. Arterioscler Thromb Vasc Biol. 2011;31:513\u20139.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"1135_CR26","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1161\/ATVBAHA.107.160192","volume":"28","author":"M Adiels","year":"2008","unstructured":"Adiels M, Olofsson S-O, Taskinen M-R, Bor\u00e9n J. Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome. Arterioscler Thromb Vasc Biol. 2008;28:1225\u201336.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"1135_CR27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1004494","volume":"10","author":"ET Lim","year":"2014","unstructured":"Lim ET, Wurtz P, Havulinna AS, Palta P, Tukiainen T, Rehnstrom K, et al. Distribution and medical impact of loss-of-function variants in the Finnish founder population. PLoS Genet. 2014;10:e1004494.","journal-title":"PLoS Genet"},{"key":"1135_CR28","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.2337\/dc20-0170","volume":"43","author":"R Lithovius","year":"2020","unstructured":"Lithovius R, Harjutsalo V, Mutter S, Gordin D, Forsblom C, Groop P-H, et al. Resistant hypertension and risk of adverse events in individuals with type 1 diabetes: a nationwide prospective study. Diabetes Care. 2020;43:1885\u201392.","journal-title":"Diabetes Care"},{"key":"1135_CR29","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.2337\/diacare.28.8.2019","volume":"28","author":"LM Thorn","year":"2005","unstructured":"Thorn LM, Forsblom C, Fagerudd J, Thomas MC, Pettersson-Fernholm K, Saraheimo M, et al. Metabolic syndrome in type 1 diabetes: association with diabetic nephropathy and glycemic control (the FinnDiane study). Diabetes Care. 2005;28:2019\u201324.","journal-title":"Diabetes Care"},{"key":"1135_CR30","doi-asserted-by":"publisher","first-page":"858","DOI":"10.2337\/db18-0573","volume":"68","author":"A Syreeni","year":"2019","unstructured":"Syreeni A, Sandholm N, Cao J, Toppila I, Maahs DM, Rewers MJ, et al. Genetic determinants of glycated hemoglobin in type 1 diabetes. Diabetes. 2019;68:858\u201367.","journal-title":"Diabetes"},{"key":"1135_CR31","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.1681\/ASN.2019030218","volume":"30","author":"RM Salem","year":"2019","unstructured":"Salem RM, Todd JN, Sandholm N, Cole JB, Chen W-M, Andrews D, et al. Genome-wide association study of diabetic kidney disease highlights biology involved in glomerular basement membrane collagen. J Am Soc Nephrol. 2019;30:2000\u201316.","journal-title":"J Am Soc Nephrol"},{"key":"1135_CR32","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/s41586-021-04064-3","volume":"600","author":"SE Graham","year":"2021","unstructured":"Graham SE, Clarke SL, Wu K-HH, Kanoni S, Zajac GJM, Ramdas S, et al. The power of genetic diversity in genome-wide association studies of lipids. Nature. 2021;600:675\u20139.","journal-title":"Nature."},{"key":"1135_CR33","unstructured":"FinnGen study. FinnGen GWAS result browser [Internet]. https:\/\/r7.finngen.fi. Accessed 27 June 2022."},{"key":"1135_CR34","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/s00125-007-0858-y","volume":"51","author":"N Tolonen","year":"2008","unstructured":"Tolonen N, Forsblom C, Thorn L, Wad\u00e9n J, Roseng\u00e5rd-B\u00e4rlund M, Saraheimo M, et al. Relationship between lipid profiles and kidney function in patients with type 1 diabetes. Diabetologia. 2008;51:12\u201320.","journal-title":"Diabetologia."},{"key":"1135_CR35","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1021\/pr201036j","volume":"11","author":"V-P M\u00e4kinen","year":"2012","unstructured":"M\u00e4kinen V-P, Tynkkynen T, Soininen P, Peltola T, Kangas AJ, Forsblom C, et al. Metabolic diversity of progressive kidney disease in 325 patients with type 1 diabetes (the FinnDiane Study). J Proteome Res. 2012;11:1782\u201390.","journal-title":"J Proteome Res"},{"key":"1135_CR36","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1111\/joim.12026","volume":"273","author":"V-P M\u00e4kinen","year":"2013","unstructured":"M\u00e4kinen V-P, Soininen P, Kangas AJ, Forsblom C, Tolonen N, Thorn LM, et al. Triglyceride-cholesterol imbalance across lipoprotein subclasses predicts diabetic kidney disease and mortality in type 1 diabetes: the FinnDiane Study. J Intern Med. 2013;273:383\u201395.","journal-title":"J Intern Med"},{"key":"1135_CR37","doi-asserted-by":"publisher","first-page":"2480","DOI":"10.2337\/db08-0332","volume":"57","author":"V-P M\u00e4kinen","year":"2008","unstructured":"M\u00e4kinen V-P, Forsblom C, Thorn LM, Wad\u00e9n J, Gordin D, Heikkil\u00e4 O, et al. Metabolic phenotypes, vascular complications, and premature deaths in a population of 4,197 patients with type 1 diabetes. Diabetes. 2008;57:2480.","journal-title":"Diabetes."},{"key":"1135_CR38","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1038\/msb.2010.93","volume":"6","author":"M Inouye","year":"2010","unstructured":"Inouye M, Kettunen J, Soininen P, Silander K, Ripatti S, Kumpula LS, et al. Metabonomic, transcriptomic, and genomic variation of a population cohort. Mol Syst Biol. 2010;6:441.","journal-title":"Mol Syst Biol"},{"key":"1135_CR39","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1093\/hmg\/ddr581","volume":"21","author":"T Tukiainen","year":"2012","unstructured":"Tukiainen T, Kettunen J, Kangas AJ, Lyytik\u00e4inen L-P, Soininen P, Sarin A-P, et al. Detailed metabolic and genetic characterization reveals new associations for 30 known lipid loci. Hum Mol Genet. 2012;21:1444\u201355.","journal-title":"Hum Mol Genet"},{"key":"1135_CR40","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1093\/aje\/kwx016","volume":"186","author":"P W\u00fcrtz","year":"2017","unstructured":"W\u00fcrtz P, Kangas AJ, Soininen P, Lawlor DA, Davey Smith G, Ala-Korpela M. Quantitative serum nuclear magnetic resonance metabolomics in large-scale epidemiology: a primer on -omic technologies. Am J Epidemiol. 2017;186:1084\u201396.","journal-title":"Am J Epidemiol"},{"key":"1135_CR41","doi-asserted-by":"crossref","unstructured":"Julkunen H, Cicho\u0144ska A, Tiainen M, Koskela H, Nybo K, M\u00e4kel\u00e4 V, et al. Atlas of plasma nuclear magnetic resonance biomarkers for health and disease in 118,461 individuals from the UK Biobank [Internet]. medRxiv. 2022:2022.06.13.22276332 Available from: https:\/\/www.medrxiv.org\/content\/10.1101\/2022.06.13.22276332v2. [Cited 2022 Oct 25].","DOI":"10.1101\/2022.06.13.22276332"},{"key":"1135_CR42","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1038\/s41588-019-0378-y","volume":"51","author":"A Bentley","year":"2019","unstructured":"Bentley A, Sung Y, Brown M, Winkler T, Kraja A, Ntalla I, et al. Multi-ancestry genome-wide gene\u2013smoking interaction study of 387,272 individuals identifies new loci associated with serum lipids. Nat Genet. 2019;51:636\u201348.","journal-title":"Nat Genet"},{"key":"1135_CR43","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","volume":"366","author":"C Baigent","year":"2005","unstructured":"Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267\u201378.","journal-title":"Lancet."},{"key":"1135_CR44","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1093\/clinchem\/18.6.499","volume":"18","author":"WT Friedewald","year":"1972","unstructured":"Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499\u2013502.","journal-title":"Clin Chem"},{"key":"1135_CR45","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/0026-0495(92)90206-P","volume":"41","author":"Y Arad","year":"1992","unstructured":"Arad Y, Ramakrishnan R, Ginsberg HN. Effects of lovastatin therapy on very-low-density lipoprotein triglyceride metabolism in subjects with combined hyperlipidemia: evidence for reduced assembly and secretion of triglyceride-rich lipoproteins. Metabolism. 1992;41:487\u201393.","journal-title":"Metabolism."},{"key":"1135_CR46","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/1471-2156-8-60","volume":"8","author":"J Wu","year":"2007","unstructured":"Wu J, Province MA, Coon H, Hunt SC, Eckfeldt JH, Arnett DK, et al. An investigation of the effects of lipid-lowering medications: genome-wide linkage analysis of lipids in the HyperGEN study. BMC Genet. 2007;8:60.","journal-title":"BMC Genet"},{"key":"1135_CR47","doi-asserted-by":"crossref","unstructured":"L\u00ea S, Josse J, Husson F. FactoMineR: an R package for multivariate analysis. J Stat Softw. 2008;25 Available from: http:\/\/www.jstatsoft.org\/v25\/i01\/. [Cited 2022 Oct 25].","DOI":"10.18637\/jss.v025.i01"},{"key":"1135_CR48","doi-asserted-by":"crossref","unstructured":"Josse J, Husson F. missMDA: a package for handling missing values in multivariate data analysis. J Stat Softw. 2016;70 Available from: http:\/\/www.jstatsoft.org\/v70\/i01\/. [Cited 2022 Oct 25].","DOI":"10.18637\/jss.v070.i01"},{"key":"1135_CR49","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1093\/cvr\/cvaa045","volume":"117","author":"AAV Antikainen","year":"2021","unstructured":"Antikainen AAV, Sandholm N, Tr\u00e9gou\u00ebt D-A, Charmet R, McKnight AJ, Ahluwalia TS, et al. Genome-wide association study on coronary artery disease in type 1 diabetes suggests beta-defensin 127 as a risk locus. Cardiovasc Res. 2021;117:600\u201312.","journal-title":"Cardiovasc Res"},{"key":"1135_CR50","unstructured":"Van der Auwera GA, O\u2019Connor BD. Genomics in the cloud: using Docker, GATK, and WDL in Terra. 1st ed. O\u2019Reilly Media; 2020."},{"key":"1135_CR51","unstructured":"UCSC. Genome Browser User\u2019s Guide [Internet]. Available from: https:\/\/genome.ucsc.edu\/goldenPath\/help\/hgTracksHelp.html#Liftover. [Cited 2022 Oct 25]."},{"key":"1135_CR52","doi-asserted-by":"publisher","unstructured":"Poplin R, Ruano-Rubio V, DePristo MA, Fennell TJ, Carneiro MO, Van der Auwera GA, et al. Scaling accurate genetic variant discovery to tens of thousands of samples. bioRxiv. 2018:201178. https:\/\/doi.org\/10.1101\/201178.","DOI":"10.1101\/201178"},{"key":"1135_CR53","doi-asserted-by":"publisher","first-page":"80","DOI":"10.4161\/fly.19695","volume":"6","author":"P Cingolani","year":"2012","unstructured":"Cingolani P, Platts A, Wang LL, Coon M, Nguyen T, Wang L, et al. A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3. Fly (Austin). 2012;6:80\u201392.","journal-title":"Fly (Austin)"},{"key":"1135_CR54","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1093\/bioinformatics\/btw079","volume":"32","author":"X Zhan","year":"2016","unstructured":"Zhan X, Hu Y, Li B, Abecasis GR, Liu DJ. RVTESTS: an efficient and comprehensive tool for rare variant association analysis using sequence data. Bioinforma Oxf Engl. 2016;32:1423\u20136.","journal-title":"Bioinforma Oxf Engl"},{"key":"1135_CR55","doi-asserted-by":"publisher","first-page":"2828","DOI":"10.1093\/bioinformatics\/btu367","volume":"30","author":"S Feng","year":"2014","unstructured":"Feng S, Liu D, Zhan X, Wing MK, Abecasis GR. RAREMETAL: fast and powerful meta-analysis for rare variants. Bioinforma Oxf Engl. 2014;30:2828\u20139.","journal-title":"Bioinforma Oxf Engl"},{"key":"1135_CR56","unstructured":"Therneau, Terry M. A package for survival analysis in R [Internet]. https:\/\/CRAN.R-project.org\/package=survival. Accessed 15 May 2021."},{"key":"1135_CR57","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1159\/000508558","volume":"84","author":"CM Moore","year":"2019","unstructured":"Moore CM, Jacobson SA, Fingerlin TE. Power and sample size calculations for genetic association studies in the presence of genetic model misspecification. Hum Hered. 2019;84:256\u201371.","journal-title":"Hum Hered"},{"key":"1135_CR58","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1002\/gepi.21645","volume":"36","author":"K Owzar","year":"2012","unstructured":"Owzar K, Li Z, Cox N, Jung S-H. Power and sample size calculations for SNP association studies with censored time-to-event outcomes. Genet Epidemiol. 2012;36:538\u201348.","journal-title":"Genet Epidemiol"},{"key":"1135_CR59","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1093\/bioinformatics\/btm091","volume":"23","author":"T Koressaar","year":"2007","unstructured":"Koressaar T, Remm M. Enhancements and modifications of primer design program Primer3. Bioinformatics. 2007;23:1289\u201391.","journal-title":"Bioinformatics."},{"key":"1135_CR60","doi-asserted-by":"publisher","first-page":"2543","DOI":"10.1093\/bioinformatics\/bts479","volume":"28","author":"JI Goldstein","year":"2012","unstructured":"Goldstein JI, Crenshaw A, Carey J, Grant GB, Maguire J, Fromer M, et al. zCall: a rare variant caller for array-based genotyping: genetics and population analysis. Bioinforma Oxf Engl. 2012;28:2543\u20135.","journal-title":"Bioinforma Oxf Engl"},{"key":"1135_CR61","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1038\/ng.3679","volume":"48","author":"P-R Loh","year":"2016","unstructured":"Loh P-R, Danecek P, Palamara PF, Fuchsberger C, Reshef YA, Finucane HK, et al. Reference-based phasing using the Haplotype Reference Consortium panel. Nat Genet. 2016;48:1443\u20138.","journal-title":"Nat Genet"},{"key":"1135_CR62","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.ajhg.2015.11.020","volume":"98","author":"BL Browning","year":"2016","unstructured":"Browning BL, Browning SR. Genotype imputation with millions of reference samples. Am J Hum Genet. 2016;98:116\u201326.","journal-title":"Am J Hum Genet"},{"key":"1135_CR63","unstructured":"SISu v3 reference panel [Internet]. FINNGEN; 2022. Available from: https:\/\/github.com\/FINNGEN\/finngen-documentation\/blob\/8a24390c151773efba74d97af7209a3acde32fa9\/methods\/genotype-imputation\/sisu-reference-panel.md. [Cited 2022 Oct 25]."},{"key":"1135_CR64","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.ajhg.2012.06.007","volume":"91","author":"S Lee","year":"2012","unstructured":"Lee S, Emond MJ, Bamshad MJ, Barnes KC, Rieder MJ, Nickerson DA, et al. Optimal unified approach for rare-variant association testing with application to small-sample case-control whole-exome sequencing studies. Am J Hum Genet. 2012;91:224\u201337.","journal-title":"Am J Hum Genet"},{"key":"1135_CR65","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.ajhg.2011.05.029","volume":"89","author":"MC Wu","year":"2011","unstructured":"Wu MC, Lee S, Cai T, Li Y, Boehnke M, Lin X. Rare-variant association testing for sequencing data with the sequence kernel association test. Am J Hum Genet. 2011;89:82\u201393.","journal-title":"Am J Hum Genet"},{"key":"1135_CR66","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s13059-016-0974-4","volume":"17","author":"W McLaren","year":"2016","unstructured":"McLaren W, Gil L, Hunt SE, Riat HS, Ritchie GRS, Thormann A, et al. The Ensembl Variant Effect Predictor. Genome Biol. 2016;17:122.","journal-title":"Genome Biol"},{"key":"1135_CR67","doi-asserted-by":"publisher","first-page":"3812","DOI":"10.1093\/nar\/gkg509","volume":"31","author":"PC Ng","year":"2003","unstructured":"Ng PC, Henikoff S. SIFT: predicting amino acid changes that affect protein function. Nucleic Acids Res. 2003;31:3812\u20134.","journal-title":"Nucleic Acids Res"},{"key":"1135_CR68","first-page":"Unit7.20","volume":"Chapter 7","author":"I Adzhubei","year":"2013","unstructured":"Adzhubei I, Jordan DM, Sunyaev SR. Predicting functional effect of human missense mutations using PolyPhen-2. Curr Protoc Hum Genet. 2013;Chapter 7:Unit7.20.","journal-title":"Curr Protoc Hum Genet"},{"key":"1135_CR69","doi-asserted-by":"publisher","first-page":"1260419","DOI":"10.1126\/science.1260419","volume":"347","author":"M Uhl\u00e9n","year":"2015","unstructured":"Uhl\u00e9n M, Fagerberg L, Hallstr\u00f6m BM, Lindskog C, Oksvold P, Mardinoglu A, et al. Proteomics. Tissue-based map of the human proteome. Science. 2015;347:1260419.","journal-title":"Science."},{"key":"1135_CR70","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1093\/hmg\/ddl077","volume":"15","author":"J Cameron","year":"2006","unstructured":"Cameron J, Holla \u00d8L, Ranheim T, Kulseth MA, Berge KE, Leren TP. Effect of mutations in the PCSK9 gene on the cell surface LDL receptors. Hum Mol Genet. 2006;15:1551\u20138.","journal-title":"Hum Mol Genet"},{"key":"1135_CR71","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.2217\/pgs.09.42","volume":"10","author":"MAV Willrich","year":"2009","unstructured":"Willrich MAV, Hirata MH, Hirata RDC. Statin regulation of CYP3A4 and CYP3A5 expression. Pharmacogenomics. 2009;10:1017\u201324.","journal-title":"Pharmacogenomics."},{"key":"1135_CR72","volume-title":"Dyslipidemias: pathophysiology, evaluation and management","author":"K Musunuru","year":"2015","unstructured":"Musunuru K. In: Garg A, editor. Dyslipidemias: pathophysiology, evaluation and management. NJ: Totowa; 2015."},{"key":"1135_CR73","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1161\/01.CIR.102.18.2197","volume":"102","author":"B Agerholm-Larsen","year":"2000","unstructured":"Agerholm-Larsen B, Tybj\u00e6rg-Hansen A, Schnohr P, Steffensen R, Nordestgaard BG. Common cholesteryl ester transfer protein mutations, decreased HDL cholesterol, and possible decreased risk of ischemic heart disease. Circulation. 2000;102:2197\u2013203.","journal-title":"Circulation."},{"key":"1135_CR74","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1016\/S0022-2275(20)41380-X","volume":"33","author":"P Lohse","year":"1992","unstructured":"Lohse P, Brewer HB, Meng MS, Skarlatos SI, LaRosa JC, Brewer HB. Familial apolipoprotein E deficiency and type III hyperlipoproteinemia due to a premature stop codon in the apolipoprotein E gene. J Lipid Res. 1992;33:1583\u201390.","journal-title":"J Lipid Res"},{"key":"1135_CR75","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/S0022-2275(20)37580-5","volume":"37","author":"P Knudsen","year":"1996","unstructured":"Knudsen P, Antikainen M, Ehnholm S, Uusi-Oukari M, Tenkanen H, Lahdenper\u00e4 S, et al. A compound heterozygote for hepatic lipase gene mutations Leu334\u2013>Phe and Thr383\u2013>Met: correlation between hepatic lipase activity and phenotypic expression. J Lipid Res. 1996;37:825\u201334.","journal-title":"J Lipid Res"},{"key":"1135_CR76","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/0006-291X(91)91336-B","volume":"179","author":"RA Hegele","year":"1991","unstructured":"Hegele RA, Little JA, Connelly PW. Compound heterozygosity for mutant hepatic lipase in familial hepatic lipase deficiency. Biochem Biophys Res Commun. 1991;179:78\u201384.","journal-title":"Biochem Biophys Res Commun"},{"key":"1135_CR77","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1080\/10408369891234273","volume":"35","author":"PW Connelly","year":"1998","unstructured":"Connelly PW, Hegele RA. Hepatic lipase deficiency. Crit Rev Clin Lab Sci. 1998;35:547\u201372.","journal-title":"Crit Rev Clin Lab Sci"},{"key":"1135_CR78","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1038\/ng.3654","volume":"48","author":"P Surendran","year":"2016","unstructured":"Surendran P, Drenos F, Young R, Warren H, Cook JP, Manning AK, et al. Trans-ancestry meta-analyses identify rare and common variants associated with blood pressure and hypertension. Nat Genet. 2016;48:1151\u201361.","journal-title":"Nat Genet"},{"key":"1135_CR79","doi-asserted-by":"publisher","first-page":"903","DOI":"10.15252\/embr.201438450","volume":"15","author":"N Fossat","year":"2014","unstructured":"Fossat N, Tourle K, Radziewic T, Barratt K, Liebhold D, Studdert JB, et al. C to U RNA editing mediated by APOBEC1 requires RNA-binding protein RBM47. EMBO Rep. 2014;15:903\u201310.","journal-title":"EMBO Rep"},{"key":"1135_CR80","doi-asserted-by":"crossref","unstructured":"Lassenius M, M\u00e4kinen V-P, Fogarty C, Per\u00e4neva L, Jauhiainen M, Pussinen P, et al. Patients with type 1 diabetes show signs of vascular dysfunction in response to multiple high-fat meals. Nutr Metab. 2014;11:28.","DOI":"10.1186\/1743-7075-11-28"},{"key":"1135_CR81","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1042\/CS20070308","volume":"114","author":"EMM Ooi","year":"2008","unstructured":"Ooi EMM, Barrett PH, Chan DC, Watts GF. Apolipoprotein C-III: understanding an emerging cardiovascular risk factor. Clin Sci. 2008;114:611\u201324.","journal-title":"Clin Sci"},{"key":"1135_CR82","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1111\/joim.13412","volume":"291","author":"F Jansson Sigfrids","year":"2022","unstructured":"Jansson Sigfrids F, Stechemesser L, Dahlstr\u00f6m EH, Forsblom CM, Harjutsalo V, Weitgasser R, et al. Apolipoprotein C-III predicts cardiovascular events and mortality in individuals with type 1 diabetes and albuminuria. J Intern Med. 2022;291:338\u201349.","journal-title":"J Intern Med"},{"key":"1135_CR83","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/j.hoc.2018.04.006","volume":"32","author":"AS Nelson","year":"2018","unstructured":"Nelson AS, Myers KC. Diagnosis, treatment, and molecular pathology of Shwachman-Diamond Syndrome. Hematol Clin N Am. 2018;32:687\u2013700.","journal-title":"Hematol Clin N Am"},{"key":"1135_CR84","first-page":"391","volume":"76","author":"T Lynch","year":"2007","unstructured":"Lynch T, Price A. The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects. Am Fam Physician. 2007;76:391\u20136.","journal-title":"Am Fam Physician"},{"key":"1135_CR85","doi-asserted-by":"crossref","unstructured":"Dt C, Gk D, Ab I, Em O, Ph B, Dc C, et al. Chronic kidney disease delays VLDL-apoB-100 particle catabolism: potential role of apolipoprotein C-III. J Lipid Res. 2009;50 Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/19542564\/. [Cited 2022 Oct 26].","DOI":"10.1194\/jlr.P900003-JLR200"},{"key":"1135_CR86","first-page":"246","volume":"5","author":"S Han","year":"2013","unstructured":"Han S, Vaziri ND, Gollapudi P, Kwok V, Moradi H. Hepatic fatty acid and cholesterol metabolism in nephrotic syndrome. Am J Transl Res. 2013;5:246\u201353.","journal-title":"Am J Transl Res"},{"key":"1135_CR87","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/nrneph.2017.155","volume":"14","author":"S Agrawal","year":"2018","unstructured":"Agrawal S, Zaritsky JJ, Fornoni A, Smoyer WE. Dyslipidaemia in nephrotic syndrome: mechanisms and treatment. Nat Rev Nephrol. 2018;14:57\u201370.","journal-title":"Nat Rev Nephrol"},{"key":"1135_CR88","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1056\/NEJM199008303230905","volume":"323","author":"J Joven","year":"1990","unstructured":"Joven J, Villabona C, Vilella E, Masana L, Albert\u00ed R, Vall\u00e9s M. Abnormalities of lipoprotein metabolism in patients with the nephrotic syndrome. N Engl J Med. 1990;323:579\u201384.","journal-title":"N Engl J Med"},{"key":"1135_CR89","doi-asserted-by":"publisher","unstructured":"Sandholm N, Ronja Hotakainen, Jani K Haukka, Jansson Sigfrids F, Emma H Dahlstr\u00f6m, Anni A Antikainen, et al. Whole-exome sequencing identifies novel protein-altering variants associated with serum apolipoprotein and lipid concentrations. figshare. Collection. https:\/\/doi.org\/10.6084\/m9.figshare.c.6269043.v3.","DOI":"10.6084\/m9.figshare.c.6269043.v3"}],"container-title":["Genome Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13073-022-01135-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13073-022-01135-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13073-022-01135-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T12:19:12Z","timestamp":1669292352000},"score":1,"resource":{"primary":{"URL":"https:\/\/genomemedicine.biomedcentral.com\/articles\/10.1186\/s13073-022-01135-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,23]]},"references-count":89,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["1135"],"URL":"https:\/\/doi.org\/10.1186\/s13073-022-01135-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.09.19.21263610","asserted-by":"object"}]},"ISSN":["1756-994X"],"issn-type":[{"value":"1756-994X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,23]]},"assertion":[{"value":"2 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the Ethical Committee of the Helsinki and Uusimaa Hospital District (491\/E5\/2006, 238\/13\/03\/00\/2015, and HUS-3313-2018, July 3rd, 2019) and the participants gave their informed consent before recruitment. This study was performed following the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"P-H.G. has received investigator-initiated research grants from Eli Lilly and Roche, is an advisory board member for AbbVie, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Cebix, Eli Lilly, Janssen, Medscape, Merck Sharp & Dohme, Mundipharma, Nestl\u00e9, Novartis, Novo Nordisk, and Sanofi, and has received lecture fees from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Elo Water, Genzyme, Merck Sharp & Dohme, Medscape, Novartis, Novo Nordisk, PeerVoice, Sanofi, and Sciarc. The remaining authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"132"}}